ADOPTION Study: Status update of a Randomised, Open-Label Exploratory Trial of Opicapone in Parkinson’s Disease
Objective: This study aims to evaluate the effect of once-daily opicapone (OPC) 50 mg versus an additional dose of levodopa (L-dopa)/dopa decarboxylase inhibitor (DDCi) to…Open-Label, Single-Arm, Exploratory Trial of Opicapone: Status Update of the OASIS (OPICAPONE IN SLEEP DISORDER) Study
Objective: This study aims to evaluate the effects of opicapone (OPC) 50 mg treatment on sleep disorders in patients with Parkinson’s disease (PD) and ‘wearing-off’.…COMT polymorphism as a genetic factor in levodopa-induced dyskinesia development in Russian patients with Parkinson’s disease
Objective: We examined the influence of single nucleotide polymorphisms (SNPs) in specific genes on levodopa-induced dyskinesia development in Parkinson’s disease patients Background: Levodopa-induced dyskinesia (LID)…OPTIMIPARK Questionnaire:a tool to optimize treatment in Parkinson´s disease.
Objective: To validate the OPTIMIPARK questionnaire as a tool to help the clinician in the adjustment of dopaminergic treatment in Parkinson´s disease(PD). Background: At early…Clinical and genetic analysis of psychosis in Parkinson’s disease
Objective: This study aimed to examine the association of seven selected polymorphisms of DRD2, ANKK1, COMT and DAT genes with Parkinson’s disease psychosis (PDP) onset.…Opicapone in fluctuating Parkinson’s disease: The daily clinical practice
Objective: To evaluate the effectiveness, tolerability and safety of opicapone as add-on to levodopa (LD) in the daily clinical practice in fluctuating Parkinson’s disease (PD)…Opicapone added to safinamide in patients affected by Parkinson’s disease for better controlling motor fluctuations
Objective: The aim of this clinical observation was to verify the sparing of levodopa in patients affected by Parkinson's disease who already started safinamide treatment for…Pharmacokinetics of Opicapone and Effect on COMT and Levodopa Pharmacokinetics in Patients with Parkinson’s Disease
Objective: To evaluate the pharmacokinetics and pharmacodynamics of opicapone in Parkinson’s disease (PD). Background: Opicapone, a highly selective COMT inhibitor, is approved in Europe and…First year of Opicapone for Advanced Parkinson Disease: real-life experience in a single Movement Disorders Unit
Objective: The aim of the study is to evaluate opicapone in an heterogeneous patient population, reflecting daily clinical practice. Background: Opicapone is a new COMT-inhibitor indicated…Association of genetic polymophisms with pharmacokinetics of levodopa in South indian PD patients
Objective: To evaluate the role of COMT gene variations on the pharmacokinetics (PK) of L-dopa in PD patients. Background: Genetic variations in enzymes (MAO-B, COMT),…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.